A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, Litzow MR, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B.
Zeidner JF, et al. Among authors: vigil ce.
Blood Cancer J. 2021 Oct 30;11(10):175. doi: 10.1038/s41408-021-00568-3.
Blood Cancer J. 2021.
PMID: 34718324
Free PMC article.
Clinical Trial.
No abstract available.